Ad disclosure
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
ImmunoGen, Inc. (NASDAQ:IMGN)
Stock Price:
$3.52
+0.045
(1.3%)
Updated
May 26, 2022 01:42 PM GMT+0000
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 775.18M |
|---|---|
| Revenue | 92.23M |
| Gross Profit | 92.23M |
| Shares Out | 220.54M |
| EPS (ttm) | -0.5888 |
| PE Ratio | -5.9140 |
| Forward PE | -4.2112 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | May 26 |
|---|---|
| Last Price | $3.52 |
| Previous Close | $3.47 |
| Change ($) | 0.045 |
| Change (%) | 1.3% |
| Day's Open | 3.51 |
| Day's Range | 3.47 - 3.515 |
| Day's Volume | 135.90K |
| 52 Week Range | 3.36 - 7.77 |
About
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
79
CEO
Mark Enyedy
Address
84 State St
Boston
Massachusetts
02109-2202
Boston
Massachusetts
02109-2202
Phone
17818950600
Website
www.immunogen.com
Ticker Symbol
IMGN
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
News
ImmunoGen, Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | -0.13 | -0.14 | -0.17 | -0.17 |
| Consensus EPS | -0.181 | -0.17 | -0.15 | -0.15 |
| Announce Time | BTO | BTO | BTO | BTO |
| Number of Estimates | 10 | 9 | 9 | 9 |
| EPS Surprise Dollar | 0.0509999990463 | 0.03 | -0.02 | -0.02 |
| EPS Report Date | 06-11-2020 | 31-07-2020 | 30-04-2020 | 30-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | -0.15 | -0.29 | -0.3 | -0.3 |
| Year Ago % Change | -13.3333399561% | 51.72% | 43.33% | 43.33% |
ImmunoGen, Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 0.03 | -0.15 | -0.29 |
| Consensus EPS | -0.05 | -0.18 | -0.33 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 10 | 10 | 10 |
| EPS Surprise Dollar | 0.08 | 0.03 | 0.04 |
| EPS Report Date | 14-02-2020 | 01-11-2019 | 01-08-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | -0.28 | -0.32 | -0.31 |
| Year Ago % Change | 110.71% | 53.13% | 6.45% |
ImmunoGen, Inc. income statements (2020) (USD)
| November 2020 | June 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 18.19M | N.A | N.A | N.A | N.A |
| Cost of Revenue | 0 | N.A | N.A | N.A | N.A |
| Gross Profit | 18.19M | N.A | N.A | N.A | N.A |
| Research & Development | 24.69M | 22.92M | 22.92M | 27.41M | 27.41M |
| Selling General & Admin | 10.23M | 9.25M | 9.25M | 8.34M | 8.34M |
| Operating Expense | 34.92M | N.A | N.A | N.A | N.A |
| Operating Income | -16.73M | -17.66M | -17.66M | -22.99M | -22.99M |
| Other Income Expense Net | 0 | -6.64M | -6.64M | -6.1M | -6.1M |
| EBIT | -16.73M | -17.66M | -17.66M | -22.99M | -22.99M |
| Interest Income | 5.67M | 6.10M | 6.10M | 5.73M | 5.73M |
| Pretax Income | -22.37M | -24.3M | -24.3M | -29.09M | -29.09M |
| Income Tax | 0 | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | -22.37M | -24.3M | -24.3M | -29.09M | -29.09M |
| Net Income Basic | -22.37M | -24.3M | -24.3M | -29.09M | -29.09M |
ImmunoGen, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 26.06M | 21.02M | 28.56M | 38.89M |
| Selling General & Admin | 9.05M | 8.37M | 7.46M | 9.58M |
| Operating Expense | N.A | N.A | N.A | N.A |
| Operating Income | 9.01M | -16.94M | -21.72M | -41.09M |
| Other Income Expense Net | -4.19M | -4.81M | -21.73M | -2.66M |
| EBIT | 9.01M | -16.94M | -21.72M | -41.09M |
| Interest Income | 5.38M | 4.30M | 3.84M | 3.46M |
| Pretax Income | 4.81M | -21.75M | -43.45M | -43.75M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 4.81M | -21.75M | -43.45M | -43.75M |
| Net Income Basic | 4.81M | -21.75M | -43.45M | -43.75M |
ImmunoGen, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 43.11M | 47.24M | 38.70M | 44.83M |
| Selling General & Admin | 8.50M | 7.21M | 6.12M | 7.47M |
| Operating Expense | N.A | N.A | N.A | N.A |
| Operating Income | -39.05M | -44.66M | -38.07M | -35.01M |
| Other Income Expense Net | -1.78M | -2.15M | -3.56M | -3.6M |
| EBIT | -39.05M | -44.66M | -38.07M | -35.01M |
| Interest Income | 2.45M | 2.57M | 2.63M | 3.07M |
| Pretax Income | -40.83M | -46.81M | -41.62M | -38.61M |
| Income Tax | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -40.83M | -46.81M | -41.62M | -38.61M |
| Net Income Basic | -40.83M | -46.81M | -41.62M | -38.61M |
ImmunoGen, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A |
| Research & Development | 39.84M | 31.69M | 35.32M |
| Selling General & Admin | 7.39M | 6.54M | 7.41M |
| Operating Expense | N.A | N.A | N.A |
| Operating Income | -9.44M | -31.12M | -5.14M |
| Other Income Expense Net | -3.68M | -25.57M | -3.73M |
| EBIT | -9.44M | -31.12M | -5.14M |
| Interest Income | 3.25M | 4.15M | 4.63M |
| Pretax Income | -13.12M | -56.68M | -8.87M |
| Income Tax | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -13.12M | -56.68M | -8.87M |
| Net Income Basic | -13.12M | -56.68M | -8.87M |
ImmunoGen, Inc. balance sheet (2020) (USD)
| November 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Current Cash | 188.22M | 219.51M | 247.30M | 247.30M |
| Receivables | 5.06M | 1.36M | 2.80M | 2.80M |
| Inventory | 0 | N.A | N.A | N.A |
| Current Assets | 219.33M | 241.37M | 270.73M | 270.73M |
| Other Current Assets | 26.06M | 6.43M | 7.65M | 7.65M |
| Short Term Investments | 26.06M | N.A | N.A | N.A |
| Long Term Investments | 28.63M | N.A | N.A | N.A |
| Property/Plant Equipment | 5.58M | 20.77M | 21.25M | 21.25M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 0 | N.A | N.A | N.A |
| Tangible Assets (Net) | -42.89M | -24.52M | -4.1M | -4.1M |
| Other Assets | 8.57M | 7.59M | 6.83M | 6.83M |
| Total Assets | 247.95M | 269.73M | 298.81M | 298.81M |
| Accounts Payable | 8.91M | 12.74M | 9.53M | 9.53M |
| Other Current Liabilities | 90.91M | 19.76M | 24.25M | 24.25M |
| Total Current Liabilities | 99.82M | 90.88M | 85.51M | 85.51M |
| Total Liabilities | 290.84M | 294.25M | 302.91M | 302.91M |
| Long Term Debt | 0 | 74.25M | 88.53M | 88.53M |
| Current Long Term Debt | 0 | 55.21M | 48.65M | 48.65M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 1.32B | 174.54M | 174.26M | 174.26M |
| Treasury Stock | 0 | N.A | N.A | N.A |
| Retained Earnings | -1.36B | -1.34B | -1.32B | -1.32B |
| Capital Surplus | N.A | 1.31B | 1.31B | 1.31B |
| Shareholder Equity | -42.89M | -24.52M | -4.1M | -4.1M |
| Other Liabilities | N.A | N.A | N.A | N.A |
ImmunoGen, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 176.23M | 204.49M | 239.83M | 270.40M |
| Receivables | 12.13M | 3.10M | 2.47M | 4.22M |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 208.90M | 225.68M | 259.38M | 289.84M |
| Other Current Assets | 5.43M | 4.96M | 6.65M | 6.71M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 22.58M | 25.04M | 26.44M | 30.43M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | -76.12M | -86.23M | -68.17M | -27.6M |
| Other Assets | 3.78M | 3.41M | 1.85M | 3.67M |
| Total Assets | 235.26M | 254.14M | 287.67M | 323.93M |
| Accounts Payable | 9.93M | 7.23M | 7.81M | 8.78M |
| Other Current Liabilities | 23.23M | 42.09M | 34.56M | 25.37M |
| Total Current Liabilities | 77.41M | 88.17M | 74.62M | 61.43M |
| Total Liabilities | 311.38M | 340.36M | 355.84M | 351.53M |
| Long Term Debt | 106.14M | 120.18M | 133.67M | 143.94M |
| Current Long Term Debt | 41.27M | 35.99M | 29.48M | 24.65M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 150.14M | 149.69M | 149.89M | 149.43M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.29B | -1.29B | -1.27B | -1.23B |
| Capital Surplus | 1.21B | 1.20B | 1.20B | 1.20B |
| Shareholder Equity | -76.12M | -86.23M | -68.17M | -27.6M |
| Other Liabilities | N.A | N.A | N.A | N.A |
ImmunoGen, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 262.25M | 303.21M | N.A | 218.38M |
| Receivables | 2.20M | 3.14M | 541K | 6.91M |
| Inventory | N.A | 1.94M | 1.89M | 368K |
| Current Assets | 278.78M | 322.71M | 364.62M | 247.43M |
| Other Current Assets | 4.46M | 6.32M | 9.89M | 5.68M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 12.89M | 13.21M | 12.03M | 12.85M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 10.97M | 46.89M | 89.19M | -36.31M |
| Other Assets | 3.71M | 3.94M | 4.44M | 4.68M |
| Total Assets | 295.38M | 339.86M | 381.08M | 264.97M |
| Accounts Payable | 11.37M | 10.35M | 12.88M | 7.79M |
| Other Current Liabilities | 33.42M | 36.98M | 28.20M | 30.82M |
| Total Current Liabilities | 70.66M | 70.37M | 63.35M | 66.23M |
| Total Liabilities | 284.41M | 292.98M | 291.89M | 301.28M |
| Long Term Debt | 124.41M | 132.97M | 138.76M | 144.07M |
| Current Long Term Debt | 25.88M | 23.04M | 22.27M | 27.62M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 149.40M | 149.05M | 149.02M | 133.02M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.18B | -1.14B | -1.09B | -1.05B |
| Capital Surplus | 1.19B | 1.19B | 1.18B | 1.02B |
| Shareholder Equity | 10.97M | 46.89M | 89.19M | -36.31M |
| Other Liabilities | N.A | N.A | N.A | N.A |
ImmunoGen, Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 267.11M | 194.85M | 150.34M |
| Receivables | 5.23M | 5.12M | 2.83M |
| Inventory | 1.04M | 2.24M | 3.48M |
| Current Assets | 276.34M | 206.96M | 161.41M |
| Other Current Assets | 2.97M | 4.75M | 4.76M |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | 14.54M | 15.62M | 16.82M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | -17.9M | -111.3M | -173.23M |
| Other Assets | 3.80M | 3.11M | 3.15M |
| Total Assets | 294.68M | 225.70M | 181.38M |
| Accounts Payable | 8.56M | 6.61M | 5.15M |
| Other Current Liabilities | 29.43M | 50.34M | 46.52M |
| Total Current Liabilities | 55.77M | 73.66M | 67.35M |
| Total Liabilities | 312.57M | 336.99M | 354.61M |
| Long Term Debt | 153.68M | 160.10M | 258.64M |
| Current Long Term Debt | 17.78M | 16.70M | 15.68M |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 132.53M | 115.56M | 89.60M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -1.03B | -1.02B | -0.96B |
| Capital Surplus | 1.01B | 0.90B | 784.66M |
| Shareholder Equity | -17.9M | -111.3M | -173.23M |
| Other Liabilities | N.A | N.A | N.A |
ImmunoGen, Inc. cash flow (2020) (USD)
| November 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -22.37M | -24.3M | -29.09M |
| Depreciation | 1.57M | 516K | 529K |
| Changes in Receivables | 4.74M | 1.44M | 9.34M |
| Changes in Inventories | 0 | N.A | N.A |
| Cash Change | -31.29M | -27.79M | 71.07M |
| Cash Flow | -87.16M | -27.46M | -27.61M |
| Capital Expenditures | -815K | -23K | -21K |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 611K | -23K | 1.41M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -214.27M | -733K | -702K |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 98.54M | -310K | 97.28M |
| Exchange Rate Effect | N.A | N.A | N.A |
ImmunoGen, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 4.81M | -21.75M | -43.45M | -43.75M |
| Depreciation | 751K | 839K | 1.24M | 1.20M |
| Changes in Receivables | -9.03M | -629K | 1.74M | -2.01M |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -28.27M | -35.33M | -30.57M | 8.14M |
| Cash Flow | -31.88M | -33.18M | -31.01M | 10.20M |
| Capital Expenditures | -83K | -407K | -228K | -2.13M |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 2.23M | -407K | -228K | -2.13M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -682K | -1.82M | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 1.38M | -1.75M | 670K | 68K |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
ImmunoGen, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -40.83M | -46.81M | -41.62M | -38.61M |
| Depreciation | 1.22M | 1.14M | 2.53M | 2.53M |
| Changes in Receivables | 0.94M | -2.6M | 6.37M | -1.68M |
| Changes in Inventories | 1.94M | -48K | -1.52M | 670K |
| Cash Change | -40.95M | -41.85M | 126.68M | -48.72M |
| Cash Flow | -41.29M | -39.86M | -35.33M | -49.96M |
| Capital Expenditures | -1.03M | -2.09M | -1.1M | -1.03M |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -1.03M | -2.09M | -1.1M | -1.03M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 1.36M | 96K | 163.10M | 2.26M |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
ImmunoGen, Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -13.12M | -56.68M | -8.87M |
| Depreciation | 1.66M | 1.37M | 1.43M |
| Changes in Receivables | -108K | -2.29M | 3.11M |
| Changes in Inventories | 1.21M | 1.24M | -257K |
| Cash Change | 72.26M | 44.51M | 23.77M |
| Cash Flow | -27.73M | 44.25M | 24.08M |
| Capital Expenditures | -269K | -68K | -342K |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -269K | -68K | -342K |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A |
| Other Financing Cash Flows | -1.7M | N.A | N.A |
| Cash Flow Financing | 100.25M | 331K | 32K |
| Exchange Rate Effect | N.A | N.A | N.A |
ImmunoGen, Inc. dividends (USD)
Total Valuation
Immunogen, Inc. has a market cap or net worth of $775.18 million. The enterprise value is $327.60 million.
Market Cap
775.18M
Enterprise Value
327.60M
Important Dates
Earnings Date
Jul 29, 2022
Ex-Dividend Date
n.a
Share Statistics
Immunogen, Inc. has 220.54 million shares outstanding.
Shares Outstanding
220.54M
Float
n.a
Valuation Ratios
The trailing PE ratio is -5.9140 and the forward PE ratio is -4.2112. Immunogen, Inc.'s PEG ratio is 0.0494.
PE Ratio
-5.9140
Forward PE
-4.2112
PS Ratio
8.3000
PB Ratio
2.5000
PEG Ratio
0.0494
Stock Price Statistics
The stock price has decreased by -0.5323%. The beta is 1.4825, so Immunogen, Inc.'s price volatility has been higher than the market average.
Beta (1Y)
1.4825
52-Week Price Change
-0.5323%
50-Day Moving Average
4.57
200-Day Moving Average
5.52
Average Volume (30 Days)
4.53M
Income Statement
In the last 12 months, Immunogen, Inc. had revenue of $92.23 million and earned $92.23 million in profits. Earnings per share was $-0.5888.
Revenue
92.23M
Gross Profit
92.23M
EBITDA
-117.07M
Earnings per Share
-0.5888
About
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
79
CEO
Mark Enyedy
Address
84 State St
Boston
Massachusetts
02109-2202
Boston
Massachusetts
02109-2202
Phone
17818950600
Website
www.immunogen.com
Ticker Symbol
IMGN
Reporting Currency
USD
Company Description
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days..